A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis

By Turkstra E.   Ng S.-K.   Scuffham P.A.  

Current Medical Research and Opinion, Vol. 27, Iss. 10, 2011-10 ,pp. : 1885-1897

Informa Healthcare

Access to resources Recommend Favorite

Safety and retention of combination triple disease‐modifying anti‐rheumatic drugs in new‐onset rheumatoid arthritis

By  

INTERNAL MEDICINE JOURNAL, Vol. 45, Iss. 12, 2015-12 ,pp. : 1266-1273

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in peripheral blood B cell subsets at diagnosis and after treatment with disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis: correlation with clinical and laboratory parameters

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 18, Iss. 4, 2015-05 ,pp. : 421-432

John Wiley & Sons Inc

Access to resources Recommend Favorite

Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 21, Iss. 1, 2018-01 ,pp. : 170-178

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

By Gibofsky Allan   Palmer William R.   Goldman John A.   Lautzenheiser Richard L.   Markenson Joseph A.   Weaver Arthur   Schiff Michael H.   Keystone Edward C.   Paulus Harold E.   Harrison Melanie J.   Whitmore James B.   Leff Jonathan A.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 169-183

Informa Healthcare

Access to resources Recommend Favorite